Hyperthyroidism
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hyperthyroidism is an early-stage landscape with 10 programs across 6 companies. The most active players are Dawnrays Pharmaceutical (Holdings) Limited, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 3 therapies are approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Dawnrays Pharmaceutical (Holdings) Limited
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Viking Therapeutics, Inc.
1 program
Boehringer Ingelheim
1 program
Leadiant Biosciences, Inc.
1 program
Pipeline
Programs by Phase
Analysis
Trial Status
12
clinical trials
Clinical Trials
Trial Activity
12 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)